BIOA (bioagelabs.com) Market Value to Book Value Ratio

Official company branding of BioAge Labs (BIOA)

BioAge Labs, Inc. (BIOA) operations are protected by the humanitarian status of medicine and remain independent of sanction wars. The operating model relies on outsourcing production and testing, which eliminates capital expenditures for manufacturing plants. The current metric stands at 0.67. Market fluctuations in the share price confirm its status as an ambitious startup, where a belief in the fight against aging and stock options retain top scientists within the team.

BIOA BioAge Labs, Inc: Market Value to Book Value in the range 09/27/2024 - 10/28/2026
Original product of BioAge Labs Inc.

This indicator reflects the size of the market premium over net assets, demonstrating how much investors are willing to pay over the book value for control of the business. By analyzing the ratio of the company's value relative to its balance sheet, one can see how the AI development potential of BioAge Labs (BIOA) in the longevity sector is priced into the capitalization, transforming tangible resources into a high-tech asset.

Main competitors

ASND: Market Capitalization to Book Value Ratio|MDGL (madrigalpharma.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio Radius Pharmaceuticals (RDUS)